TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38229357
Drug: IBI303 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI303 (40 mg subcutaneous injection every 2 weeks)
Study: 38229357
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg subcutaneous injection every 2 weeks)
Study: 38229392
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment with three Lactobacillus strains (Lactobacillus paracasei DSM 13434, Lactobacillus plantarum DSM 15312, Lactobacillus plantarum DSM 15313; 1 x 10^9 CFU)
Study: 38229914
Drug: Inhaled anesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled anesthetics after total intravenous anesthesia (TIVA)
Study: 38231017
Drug: Prednisone (PDN)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (PDN) 1 mg/kg per day from days 0 to 28 (Arm A)
Study: 38231017
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (HD-DXM) 40 mg per day for 4 days, every 14 days, for 3 consecutive courses (Arm B)
Study: 38231079
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg daily for 14 days) plus standard of care
Study: 38231126
Drug: TC (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC (treatment choice)
Study: 38231536
Drug: 8-week blended
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week blended intervention combining weekly face-to-face group sessions and a digital companion app
Study: 38231590
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of urinary CD4 + T-cell counts with proteinase-3 ANCA levels
Study: 38231621
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel applied daily
Study: 38231621
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied daily
Study: 38231623
Drug: Azithromycin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (20 mg per kilogram of body weight)
Study: 38231624
Drug: Simnotrelvir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simnotrelvir plus ritonavir (750 mg of simnotrelvir plus 100 mg of ritonavir, twice daily for 5 days)
Study: 38232249
Drug: Maintenance electroconvulsive
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance electroconvulsive therapy (M-ECT) with medication
Study: 38232692
Drug: High BAT
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High BAT volume (≥20 mL)
Study: 38232692
Drug: Low BAT
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low BAT volume (<20 mL)
Study: 38232864
Drug: Psychological pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological pain treatments
Study: 38233075
Drug: Treatment-induced minimal
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-induced minimal disease activity (MDA) at 6 months
Study: 38233075
Drug: Baseline morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline morning cortisol <13.9 nmol/L
Study: 38233083
Drug: No saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: No saline therapy
Study: 38233575
Drug: i.v. 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. 24 mg dexamethasone
Study: 38233586
Drug: anti-CD19 CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-CD19 CAR T cell therapy (axicabtagene ciloleucel)
Study: 38233586
Drug: standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care (salvage chemotherapy followed by hematopoietic transplantation)
Study: 38233608
Drug: DROP-IN +
Approvals — FDA: no, EMA: no, PMDA: no
Description: DROP-IN + LaproFlex combination
Study: 38233784
Drug: Ballet-based dance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ballet-based dance programme (12 one-weekly sessions)
Study: 38233810
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously every 3 weeks for up to 6 cycles
Study: 38233816
Drug: Thymosin α1
Normalized name: chymosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin α1 (1.6 mg subcutaneous injections for 24 weeks, daily for the first 2 weeks, biweekly for the next 22 weeks)
Study: 38233878
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) at 0.07 mg/kg/day initially, adjusted by trough levels
Study: 38233878
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) at a maximum of 2000 mg/day
Study: 38233885
Drug: IVIg (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (1.0 g/kg in open-label extension)
Study: 38233908
Drug: CleverCap pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CleverCap pill bottle linked to the WiseApp (intervention)
Study: 38234020
Drug: Mebendazole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (50 mg/kg/day, 100 mg/kg/day, 200 mg/kg/day) with bevacizumab (10 mg/kg/dose) and irinotecan (150 mg/m2)
Study: 39681895
Drug: Nthabi conversational
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nthabi conversational agent system for family planning education
Study: 38234736
Drug: Nthabi conversational
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nthabi conversational agent system for folic acid education
Study: 38235421
Drug: RC48 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC48 2.0 mg/kg plus toripalimab 3 mg/kg, q2w
Study: 38235421
Drug: RC48 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC48 2.5 mg/kg plus toripalimab 3 mg/kg, q2w
Study: 38235421
Drug: RC48 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC48 2.5 mg/kg plus toripalimab 3 mg/kg, q2w (HER2-positive population)
Study: 38235421
Drug: RC48 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC48 2.5 mg/kg plus toripalimab 3 mg/kg, q2w (low HER2 expressing population)
Study: 38235512
Drug: Sovleplenib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sovleplenib (600 mg q.d. for >65 kg or 400 mg q.d. for ≤65 kg)
Study: 38235512
Drug: Sovleplenib (200-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sovleplenib (200-800 mg once daily or 200 mg twice daily)
Study: 38235519
Drug: Carfilzomib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib (20 mg/m2 intravenously in cycle 1 on days 1 and 2, then 56 mg/m2 from day 8 onwards), thalidomide (100 mg orally in the evening), and dexamethasone (40 mg weekly, 20 mg for patients ≥75 years) for 18 months.
Study: 38235519
Drug: Carfilzomib, thalidomide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib, thalidomide, and dexamethasone (KTd) treatment.
Study: 38236249
Drug: Ziv-aflibercept (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziv-aflibercept (2-4 mg/kg) plus pembrolizumab (2 mg/kg), administered intravenously every 2 weeks
Study: 38236431
Drug: Once-weekly subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly subcutaneous semaglutide (0.5 mg and 1.0 mg)
Study: 38236431
Drug: Once-daily sitagliptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily sitagliptin (100 mg)
Study: 38236575
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg twice daily with Durvalumab 1,500 mg on day 1 every 4 weeks
Study: 38236575
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control of continued platinum-based therapy
Study: 38236638
Drug: 7-week self-help
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-week self-help program delivered through a mobile app involving 7 weekly 10-minute videos
Study: 38236638
Drug: Treatment-as-usual condition
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual condition (waitlist control)
Study: 38237077
Drug: DA-EPOCH-R with
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-EPOCH-R with ixazomib (3 mg established as recommended phase 2 dose), administered for 6 cycles with ixazomib given twice per 21-day cycle; responders continued weekly ixazomib maintenance for up to 1 year.
Study: 38237263
Drug: Mirror movement
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirror movement therapy ankle exercises for 15 minutes daily
Study: 38237263
Drug: Mirror movement
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirror movement therapy ankle exercises for 30 minutes daily
Study: 38237263
Drug: Mirror movement
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirror movement therapy ankle exercises for 50 minutes daily
Study: 38237263
Drug: Mirror movement
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirror movement therapy ankle exercises for 40 minutes daily
Study: 38237263
Drug: Mirror movement
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirror movement therapy ankle exercises for 35 minutes daily
Study: 38237263
Drug: Mirror movement
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirror movement therapy ankle exercises (various doses)
Study: 38237373
Drug: Surufatinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib (250 mg orally, once daily) plus toripalimab (240 mg intravenously, once every 3 weeks)
Study: 38237620
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine 5 mg orally twice daily for 14 days
Study: 38237620
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 14 days
Study: 38237675
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg daily for 7 days followed by 5 mg/kg daily for 7 days)
Study: 38238052
Drug: Early resumption
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early resumption of oral intake (E group)
Study: 38238052
Drug: Delayed resumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed resumption of oral intake (D group)
Study: 38238050
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) after interhospital transfer
Study: 38238055
Drug: Intraperitoneal irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal irinotecan (75 mg) with concomitant mFOLFOX4 and bevacizumab
Study: 38238182
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Structured Exercise and Lifestyle
Study: 38238182
Drug: Non-responders to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-responders to initial treatment
Study: 38238194
Drug: EUS-guided fine
Normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EUS-guided fine needle injection (EUS-FNI) of large surface area microparticle paclitaxel (LSAM-PTX) at a concentration of 15 mg/mL, with a mean of 4 doses administered (mean dose/cyst: 73 ± 31 mg)
Study: 38238599
Drug: Frequent CC
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frequent CC screening
Study: 38238599
Drug: Infrequent CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrequent CC screening
Study: 38238620
Drug: Intravenous tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tenecteplase (TNK) plus Dl-3-n-Butylphthalide (NBP)
Study: 38238616
Drug: Allogeneic CD19-specific
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic CD19-specific CAR-NK cells expressing anti-CD19 chimeric antigen receptor and interleukin-15 (CAR19/IL-15)
Study: 38238666
Drug: Postoperative nadir
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative nadir platelet count ≤ 99 × 10^9/L
Study: 38238809
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (rehabilitation + optional delayed surgery)
Study: 38239359
Drug: Apatinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (250 mg orally once daily) + Camrelizumab (200 mg)
Study: 38240204
Drug: Low-dose edoxaban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose edoxaban (15 mg once daily)
Study: 38240536
Drug: Histamine-2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine-2 receptor antagonist (SUP)
Study: 38240791
Drug: High-dose enoxaparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose enoxaparin 30 mg q12hours (E30q12)
Study: 38240791
Drug: Standard-dose enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose enoxaparin 40 mg q24hours (E40q24)
Study: 38240791
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) 5000 Units q8hours
Study: 38240916
Drug: Chemotherapy (paclitaxel/docetaxel)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (paclitaxel/docetaxel)
Study: 38241058
Drug: UFH (unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH (unfractionated heparin) median dose 8000 IU; clopidogrel 600 mg
Study: 38241059
Drug: Estetrol (E4)
Normalized name: estetrol
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Estetrol (E4) 15 mg for 12 weeks
Study: 38241059
Drug: Estetrol (E4)
Normalized name: estetrol
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Estetrol (E4) 2.5 mg for 12 weeks
Study: 38241247
Drug: Inhaled nitrous
Normalized name: nitrous oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitrous oxide (1 hour at 50% concentration) plus intravenous saline (100mL)
Study: 38241247
Drug: Inhaled oxygen
Normalized name: oxygen Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled oxygen (1 hour at 50% concentration) plus intravenous midazolam (0.02 mg/kg in 100mL, up to 2mg)
Study: 38241247
Drug: Inhaled oxygen
Normalized name: oxygen Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled oxygen plus intravenous midazolam
Study: 38241643
Drug: 480 mg
Normalized name: magaldrate 480 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg letermovir once daily orally or intravenously (240 mg with cyclosporin A)
Study: 38241661
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins or methylprednisolone
Study: 38242333
Drug: Behavioral Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Activation Therapy for Depression (BATD)
Study: 38242717
Drug: Lenvatinib 20
Normalized name: LENVATINIB 20MG DAILY DOSE PACK,10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 20 mg once daily plus pembrolizumab 200 mg every 3 weeks for 35 cycles
Study: 38242720
Drug: Immune-chemo (Ipilimumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune-chemo (Ipilimumab and Nivolumab combined with anthracycline-based chemotherapy)
Study: 38242720
Drug: Chemo-only (anthracycline-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-only (anthracycline-based chemotherapy)
Study: 38243094
Drug: Preoperative copeptin
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative copeptin (> 14 pmol·L)
Study: 38243266
Drug: Continuous perioperative
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous perioperative ketamine infusion
Study: 38243266
Drug: Single-dose ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ketamine in the postanesthesia care unit
Study: 38243272
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: PAI with 100 mg bupivacaine per knee (totaling 300 mg bupivacaine for ACB and PAI)
Study: 38243272
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: PAI with 50 mg bupivacaine per knee (totaling 200 mg bupivacaine for ACB and PAI)
Study: 38243272
Drug: ACB combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACB combined with 100 mg bupivacaine and PAI with another 100 mg bupivacaine
Study: 38243272
Drug: ACB combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACB combined with 100 mg bupivacaine and PAI with 200 mg bupivacaine
Study: 38243296
Drug: Quabodepistat (QBS)
Normalized name: Quabodepistat
DrugBank: Quabodepistat (DB17770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quabodepistat (QBS) in combination with delamanid and bedaquiline for 4 months
Study: 38243296
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (rifampicin, isoniazid, ethambutol, and pyrazinamide) for 6 months
Study: 38243311
Drug: Broad-spectrum prophylaxis
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum prophylaxis with vancomycin 1 g and gentamicin 5 mg/kg parenterally
Study: 38243752
Drug: Relugolix combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix combination therapy (CT) - relugolix 40 mg, oestradiol 1 mg, norethisterone acetate 0.5 mg, once daily for up to 104 weeks.
Study: 38243752
Drug: Delayed relugolix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed relugolix CT (relugolix 40 mg monotherapy for 12 weeks, followed by relugolix CT).
Study: 38243906
Drug: ANV419 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANV419 administered by intravenous infusion at doses of 243 µg/kg (RP2D/MTD)
Study: 38244105
Drug: Hypofractionated chemoradiation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated chemoradiation (40 Gy of 3D-conformal RT in 15 fractions over 3 weeks with concurrent weekly cisplatin 40 mg/m2)
Study: 38244105
Drug: Standard chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemoradiation (45 Gy in 25 fractions over 5 weeks with concurrent weekly cisplatin 40 mg/m2)
Study: 38244384
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy-Taking it Further (MBCT-TiF)
Study: 38244557
Drug: Oral antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antimicrobial therapy
Study: 38244557
Drug: Intravenous standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous standard therapy
Study: 38244557
Drug: Oral switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral switch antimicrobial therapy
Study: 38244927
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan (SG) administered at 10 mg/kg intravenously on days 1 and 8 of 21-day cycles
Study: 38245015
Drug: Up-front ultrasound-guided
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up-front ultrasound-guided pleural pigtail catheter thoracentesis in addition to standard pharmacological therapy
Study: 38245015
Drug: Standard pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacological therapy only
Study: 38245724
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus Ticagrelor for one month, followed by five months Ticagrelor monotherapy, and then Aspirin monotherapy for six months (Experimental group)
Study: 38245724
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus Ticagrelor for 12 months (Reference group)
Study: 38246526
Drug: Licorice (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licorice (100 mg GA/d)
Study: 38247010
Drug: Topical 0.05%
Normalized name: ingenol topical 0.05% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.05% cyclosporine A and 0.1% sodium hyaluronate
Study: 38247190
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) oral pellets (40/10 mg) administered twice daily
Study: 38247190
Drug: ABC/3TC (60/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABC/3TC (60/30 mg) dispersible tablets
Study: 38249336
Drug: Recent exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent exposure to chemotherapy
Study: 38249543
Drug: Dalbavancin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalbavancin (two doses administered 1 week apart)
Study: 38249987
Drug: Inhaled amikacin
Normalized name: amikacin Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled amikacin (0.4 g twice daily, 5-7 days monthly for 3 months)
Study: 38249987
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment recommended by GOLD 2019 report
Study: 38250251
Drug: Monoclonal gammopathy
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal gammopathy (MG) in patients with thrombotic microangiopathy (TMA)
Study: 38250275
Drug: Electro-acupuncture (EA)
Normalized name: ELECTRODE SPRAY,ELECTRO MIST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture (EA) and MRI-navigated rTMS therapy
Study: 38250275
Drug: Antidepressants (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (first-line treatment for PSD)
Study: 38250282
Drug: Two-day training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-day training program based on Acceptance and Commitment Therapy (ACT)